How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

To use this trace, just keep clicking on the ``Make one step'' button. You can use the ``Finish this call'' button to skip to the step after finishing the current level. The call stack in the display ...

Ben Taylor, CFO of Recursion, here with us. Thanks so much for joining us. Sure. Great. And first of all, thanks for having us here, Tommie. This is always a terrific conference and great to be here.

Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $3.06, moving -5.12% from the previous trading session. This change lagged the S&P 500's daily loss of 1.62%. Meanwhile, the Dow ...

Buy: Anthropic exposure via its likely IPO/secondary path (e.g., IPO allocation or liquid proxy like AI-safety/compute beneficiaries). Rationale: Anthropic is pushing “slow/pause” policy while still ...

Buffer overflow vulnerabilities have driven remote code execution for decades and keep appearing in critical network ...

In the AI value chain, application-layer leaders like Palantir and ServiceNow may win long term as chip/cloud margins ...

The companies at the frontier of artificial intelligence should be ready to slow down, one of the fastest-moving among them says. Anthropic, the maker of the Claude chatbot, has claimed AI systems may ...

The loop takes agentic AI a step further, by authorizing a swarm of agents to work continuously in the background, endlessly.

When AI Becomes a Self-Improving Strategic Asset The Battlefield That Exists Only in Code Imagine a commander who never ...

British mathematician Jack Good coined the term “intelligence explosion” 61 years ago to describe what would happen when an intelligent machine entered a runaway cycle of fully automated ...